Bartlett & CO. Wealth Management LLC Lowers Position in Danaher Corporation $DHR

Bartlett & CO. Wealth Management LLC trimmed its stake in shares of Danaher Corporation (NYSE:DHR) by 1.3% in the 2nd quarter, HoldingsChannel.com reports. The fund owned 70,494 shares of the conglomerate’s stock after selling 939 shares during the period. Bartlett & CO. Wealth Management LLC’s holdings in Danaher were worth $13,934,000 at the end of the most recent reporting period.

Several other hedge funds have also bought and sold shares of the stock. Hills Bank & Trust Co raised its stake in Danaher by 0.3% in the 1st quarter. Hills Bank & Trust Co now owns 18,015 shares of the conglomerate’s stock worth $3,693,000 after acquiring an additional 53 shares during the last quarter. Worth Financial Advisory Group LLC raised its stake in shares of Danaher by 4.6% in the second quarter. Worth Financial Advisory Group LLC now owns 1,195 shares of the conglomerate’s stock worth $236,000 after purchasing an additional 53 shares during the last quarter. Sageworth Trust Co boosted its position in Danaher by 2.3% in the first quarter. Sageworth Trust Co now owns 2,404 shares of the conglomerate’s stock valued at $493,000 after buying an additional 54 shares during the last quarter. 1834 Investment Advisors Co. increased its holdings in Danaher by 3.3% in the 1st quarter. 1834 Investment Advisors Co. now owns 1,666 shares of the conglomerate’s stock worth $342,000 after buying an additional 54 shares during the period. Finally, Bruce G. Allen Investments LLC raised its position in Danaher by 13.1% during the 2nd quarter. Bruce G. Allen Investments LLC now owns 467 shares of the conglomerate’s stock worth $92,000 after buying an additional 54 shares during the last quarter. Hedge funds and other institutional investors own 79.05% of the company’s stock.

Danaher Trading Up 6.4%

Shares of NYSE:DHR opened at $198.05 on Wednesday. The business’s 50 day moving average price is $199.55 and its 200-day moving average price is $197.31. Danaher Corporation has a 1 year low of $171.00 and a 1 year high of $279.41. The firm has a market capitalization of $141.82 billion, a price-to-earnings ratio of 42.14, a price-to-earnings-growth ratio of 2.65 and a beta of 0.75. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.62 and a quick ratio of 1.22.

Danaher (NYSE:DHR) last posted its quarterly earnings data on Tuesday, July 22nd. The conglomerate reported $1.80 earnings per share for the quarter, topping analysts’ consensus estimates of $1.64 by $0.16. The company had revenue of $5.94 billion during the quarter, compared to analysts’ expectations of $5.83 billion. Danaher had a net margin of 14.21% and a return on equity of 10.70%. The firm’s revenue for the quarter was up 3.4% on a year-over-year basis. During the same period in the prior year, the business posted $1.72 earnings per share. Danaher has set its FY 2025 guidance at 7.700-7.800 EPS. On average, equities research analysts forecast that Danaher Corporation will post 7.63 earnings per share for the current fiscal year.

Danaher Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, October 31st. Investors of record on Friday, September 26th will be given a dividend of $0.32 per share. This represents a $1.28 annualized dividend and a dividend yield of 0.6%. The ex-dividend date is Friday, September 26th. Danaher’s dividend payout ratio is 27.23%.

Analyst Upgrades and Downgrades

DHR has been the subject of several recent research reports. Deutsche Bank Aktiengesellschaft reduced their target price on shares of Danaher from $240.00 to $235.00 in a report on Thursday, June 5th. Scotiabank upgraded Danaher from a “sector perform” rating to a “sector outperform” rating and set a $275.00 price objective for the company in a research note on Friday, July 11th. Wells Fargo & Company lowered their target price on Danaher from $210.00 to $205.00 and set an “equal weight” rating on the stock in a research note on Wednesday, July 23rd. Bank of America decreased their price target on Danaher from $230.00 to $220.00 and set a “buy” rating for the company in a report on Monday, September 22nd. Finally, UBS Group dropped their price objective on shares of Danaher from $240.00 to $225.00 and set a “buy” rating on the stock in a research note on Wednesday, July 23rd. Seventeen equities research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. Based on data from MarketBeat.com, Danaher currently has a consensus rating of “Moderate Buy” and an average target price of $245.91.

Insider Transactions at Danaher

In related news, Director Teri List sold 2,778 shares of Danaher stock in a transaction dated Friday, August 22nd. The stock was sold at an average price of $211.06, for a total value of $586,324.68. Following the sale, the director directly owned 20,751 shares in the company, valued at approximately $4,379,706.06. The trade was a 11.81% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Insiders own 11.20% of the company’s stock.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.